Form 4: Virios Therapeutics Director, John C. Thomas, Acquires Stock Options

Director John C. Thomas acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.

Summary

• On February 26, 2024, John C. Thomas, a director of Virios Therapeutics, Inc., acquired stock options.
• The stock options grant the right to buy 4,167 shares of common stock at an exercise price of $0.357 per share.
• These options vest 100% on February 26, 2025, one year after the grant date, and expire on February 26, 2034.
• Following the transaction, Thomas directly owns 4,167 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of stock options to a director can be viewed as mildly positive, suggesting confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry, aligning their interests with those of shareholders.
• The vesting schedule of one year is fairly standard.

Key Dates

Keywords

Virios Therapeutics, Stock Options, Director, VIRI, Beneficial Ownership, Form 4, SEC